[Reuters] - Drug maker Dendreon Corp is looking for a suitor after sales for its lead product, prostate cancer drug Provenge, were weaker than expected, according to a Bloomberg report. The Seattle-based company is ...
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment